These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21312292)

  • 21. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: case series.
    Toren P; Ratner S; Laor N; Lerer-Amisar D; Weizman A
    Neuropsychobiology; 2005; 51(4):239-42. PubMed ID: 15897675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.
    Spencer T; Biederman J; Wilens T; Prince J; Hatch M; Jones J; Harding M; Faraone SV; Seidman L
    Am J Psychiatry; 1998 May; 155(5):693-5. PubMed ID: 9585725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD).
    Conners CK; Levin ED; Sparrow E; Hinton SC; Erhardt D; Meck WH; Rose JE; March J
    Psychopharmacol Bull; 1996; 32(1):67-73. PubMed ID: 8927677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder.
    Tehrani-Doost M; Moallemi S; Shahrivar Z
    J Child Adolesc Psychopharmacol; 2008 Apr; 18(2):179-84. PubMed ID: 18439114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reboxetine for the treatment of patients with Cocaine Dependence Disorder.
    Szerman N; Peris L; Mesías B; Colis P; Rosa J; Prieto A;
    Hum Psychopharmacol; 2005 Apr; 20(3):189-92. PubMed ID: 15799010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of reboxetine in bulimia nervosa: a pilot study.
    Fassino S; Daga GA; Boggio S; Garzaro L; Pierò A
    J Psychopharmacol; 2004 Sep; 18(3):423-8. PubMed ID: 15358988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reboxetine use in the treatment of attention-deficit/hyperactivity disorder.
    Cak HT; Cetin FC
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):803-4. PubMed ID: 17201625
    [No Abstract]   [Full Text] [Related]  

  • 33. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reboxetine in clinical practice: a review.
    Sepede G; Corbo M; Fiori F; Martinotti G
    Clin Ter; 2012 Jul; 163(4):e255-62. PubMed ID: 23007832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Kotarski M; Spencer T
    J Clin Psychopharmacol; 2010 Oct; 30(5):549-53. PubMed ID: 20814332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Attention-deficit/hyperactivity disorder (ADHS) in adulthood].
    Kordon A; Kahl KG
    Psychother Psychosom Med Psychol; 2004; 54(3-4):124-36. PubMed ID: 15037976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is a significant response in drug studies of attention-deficit/hyperactivity disorder: statistical significance is necessary, but is it sufficient?
    Sangal RB; Sangal JM
    Psychopharmacol Bull; 2003; 37(2):50-8. PubMed ID: 14566214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: a long-term follow-up study.
    Toren P; Ratner S; Weizman A; Lask M; Ben-Amitay G; Laor N
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):803-12. PubMed ID: 18315452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.